Why a PFAS Blood Test Cannot Tell You Your Future Health
The Chemicals We Carry
Blood and urine samples could help establish everyday chemical exposure, but the findings will need careful interpretation.
Britain is investigating a question that sounds straightforward until the results arrive: how much of the chemical pollution around us can be measured inside us?
On 3 November 2026, the UK Health Security Agency announced a human biomonitoring study examining PFAS, often called “forever chemicals”, alongside other substances. Initial findings from the programme are expected in 2027.
The purpose is to establish background exposure and strengthen the evidence available for future health research. Finding a chemical in a sample does not, by itself, establish that it has caused illness. Equally, uncertainty about the consequences does not make measuring exposure pointless.
The study addresses the space between those two statements: what can scientists learn about a population before they can offer a clear interpretation to an individual?
Why These Chemicals Are So Persistent
PFAS stands for per- and polyfluoroalkyl substances, a large family of manufactured chemicals. Their useful properties include resistance to water, grease and heat. Applications have included non-stick cookware, fabric treatments, food packaging and firefighting foams.
Those properties help explain both their commercial appeal and the difficulty of managing them after release. The Drinking Water Inspectorate describes PFAS as highly resistant to biodegradation. A material designed to endure during use can also create problems when it persists beyond the setting where it was wanted.
However, PFAS is a family name, not a single ingredient. Treating every member as chemically or biologically identical would obscure important differences. A finding about one compound cannot automatically become a finding about every product associated with the wider group.
“Forever chemicals” is therefore a useful description of environmental persistence, but a poor substitute for identifying the substance actually being measured.
What Britain Is Testing
The programme will examine blood and urine samples collected through the Health Survey for England. Alongside PFAS, the announced testing includes lead, arsenic, bisphenols, phthalates and flame retardants.
There is an important geographical qualification. Although the announcement describes a UK research objective, the named survey supplies samples from England. Findings should be interpreted according to the people represented in that sample, rather than assumed to describe every community across all four UK nations equally well.
The work also predates this week’s announcement. A parliamentary answer published on 4 November 2025 explained that a biomonitoring module had been incorporated into the Health Survey for England’s 2022/23 programme following work by UKHSA and Imperial College London.
That chronology matters. A newly published announcement is not evidence that every sample was collected this week. When results appear, the dates of collection will help determine which period of exposure they describe.
A Background Level Is Not a Safety Limit
The government’s response to Parliament’s Environmental Audit Committee describes the development of reference values for environmental pollutants through a representative English population sample.
Such values provide a basis for comparison. Without them, a measurement can be difficult to place: researchers may know that a substance is present without knowing how unusual that concentration is among comparable people.
But “usual” and “safe” answer different questions. A reference value describes the distribution of exposure. A health-based limit requires evidence about harm. Something does not become harmless because it is widespread, and a result above a population average does not automatically establish disease.
The practical value lies in better questions. Are some groups consistently more exposed? Would repeated measurements show changes over time? Do apparent differences survive checks on age, sampling and laboratory methods? These are possible uses of a stronger evidence base, rather than findings the new announcement has already established.
Why One Blood Result Cannot Explain Everything
UKHSA’s public guidance says exposure can come from several sources, including food, drinking water, air and everyday products. A blood result cannot identify which source was responsible.
This makes attribution difficult. Measuring a chemical inside someone does not identify a particular factory, water supply or purchase as its origin. Establishing that connection requires additional evidence about exposure routes.
The agency does not currently recommend individual PFAS testing through the NHS or privately. Its guidance says such tests cannot predict future health problems or establish the cause of existing illness.
A population study and a clinical test have different jobs. Researchers can use patterns across participants to guide further investigation. A clinician needs a result that can help determine what should happen for the person sitting in front of them. Producing a number is only one part of that process.
What the Health Evidence Actually Shows
In September 2026, UKHSA published a rapid review focused on long-term exposure associated with industrial sources of PFAS. Its scope was specific: it included cohort studies and excluded papers examining certain biological markers rather than health outcomes.
The review identified evidence suggesting an association between PFOS, or mixtures containing it, and lower birthweight. For many other outcomes, the included evidence was insufficient to determine whether an association existed.
The distinction between “insufficient evidence” and “evidence of no effect” is crucial. A review may be unable to settle a question because too few suitable studies exist, because findings vary, or because its inclusion rules leave parts of the broader literature outside its scope.
UKHSA’s conclusion about communities near industrial sites should therefore be read within that review’s boundaries. It does not resolve every question about every PFAS compound, exposure route or health outcome.
Why the Cancer Classifications Need Context
The International Agency for Research on Cancer has classified PFOA as carcinogenic to humans and PFOS as possibly carcinogenic to humans.
These classifications concern the strength of evidence that an agent can cause cancer. They do not specify a person’s likelihood of developing cancer at a particular measured concentration.
For PFOA, the agency’s classification drew on sufficient evidence in experimental animals and strong evidence about cancer-related mechanisms in exposed humans. It also identified limited human evidence concerning kidney and testicular cancer.
That is a serious finding, but it cannot be converted into a personal prognosis from a blood test. Nor should the classification of PFOA be attached indiscriminately to the entire PFAS family.
Hazard identification and individual risk assessment are connected stages of scientific work. They are not interchangeable conclusions.
What to Look for When the Results Arrive
The most informative results will explain which compounds were tested, how many samples were analysed, when those samples were collected and which population they represent. The spread of measurements will matter alongside any headline average.
Those details will determine what comparisons are justified. A small sample cannot automatically answer questions about a particular occupation or neighbourhood. Changes between studies also require care: different participants or analytical methods can complicate an apparent trend.
There is a useful parallel with interpreting tests on consumer products. Evidence about hazardous substances in counterfeit cosmetics depends on understanding exactly what was sampled. The same discipline applies here, even though the substances, circumstances and research questions differ.
Britain’s study can make future decisions better informed by establishing a clearer starting point. Its eventual value will depend on whether researchers and policymakers use those measurements to investigate exposure, test explanations and assess change. The laboratory result begins that work; it does not finish it.
Sources
UK Health Security Agency — UKHSA Launches Human Biomonitoring Study — Announcement dated 3 November 2026, substances being measured and expected initial findings in 2027.
Drinking Water Inspectorate — PFAS and Forever Chemicals — Uses, chemical family and environmental persistence.
UK Parliament — Written Question 85312 — Answer dated 4 November 2025 explaining the biomonitoring module in the Health Survey for England 2022/23 programme.
Environmental Audit Committee — Addressing the Risks from Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS): Government Response — Development of reference values and the English population sampling framework. Its earlier timetable is superseded here by the November announcement.
UK Health Security Agency — Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS): General Information — Exposure routes and limits of individual testing.
UK Health Security Agency — The Health Impacts from Industrial Sources of PFAS: A Rapid Review — Review scope, birthweight association and unresolved health outcomes.
International Agency for Research on Cancer — IARC Monographs Evaluate the Carcinogenicity of PFOA and PFOS — Cancer classifications, evidential basis and distinction between hazard and risk.
Next Reads
Toxic Substances Found in Counterfeit Cosmetics: What Shoppers Need to Know — How to distinguish a chemical finding from wider claims about exposure and harm.
